Dr. Xu has extensive expertise in various aspects of intellectual property law and business including patent, design, and trademark prosecution, invalidation, and litigation; trade secrets protection and litigation; technology licensing and transfer; enterprise intellectual property strategies; and more. She also provides advice to clients on laws and regulations related to drug approval processes by the Food and Drug Administration. Dr. Xu has rich experience in providing intellectual property services in life science fields and some mechanical, electronic and other technical fields.

 

Dr. Xu has been working in the intellectual property industry since 2000 and has served many international well-known enterprises as clients. She specializes in handling European and American intellectual property legal affairs and is currently an attorney-at-law in the courts of New York and New Jersey and a registered patent attorney before the U.S. patent and Trademark Office. Dr. Xu joined in Lung Tin in 2009.

 

Dr. Xu has conducted in-depth research on patent law, trademark law and related practices in China, Europe and the United States. She actively engages in intellectual property research and has been invited to give speeches and publish numerous professional articles worldwide by major international organizations. Dr. Xu has also been invited as a member of the delegation of the State Intellectual Property Office to the United States to exchange views.

Lung Tin Intellectual Property Agent Ltd., Partner, Board Member, US attorney, US registered patent attorney

Goodwin Procter LLP (New York), Patent Attorney

Fish & Richardson P.C. (Boston, New York), Patent Agent

Orchid BioSciences, Inc. (Princeton, New Jersey), Senior Scientist

Author, “Trade Secrets - China”, June 2021 Issue, Les Nouvelles - Journal of the Licensing Executives Society, Volume LVI No. 2

Author, “Commercializing Patented Technologies at Chinese Universities”, January 2019 Issue, LESI Les Nouvelles

Lecturer, “Introduction to Hatch-Waxman Act and ANDA Litigation in the U.S.”, March 2018, Shanghai, Development of Drug Innovation and Generic Drug Symposium 

Author, “SMEs: Patent Challenges and Policies in China”, September 2017 Issue, LESI Les Nouvelles, Volume LII Number 3 [ISSN 0270-174X]

Moderator, “Workshop: Asian Patent Challenge”, May 2016, LESI Annual Conference 2016

Speaker, “Patent Litigation: China Practice”, January 2014, the Netherlands, C5’s 6th Forum on Pharma & Biotech

Speaker, “Sino-U.S. Patent Practice Symposium”, 2013, U.S., Member of China Delegation invited by SIPO